Hemispherx Biopharma Responding to FDA’s Ampligen Questions

Philadelphia Business Journal -- Hemispherx Biopharma said Monday its plans to “complete all outstanding queries” from the Food and Drug Administration regarding the company’s new drug application for Ampligen this month and next.